Work

Enhancing HER2-low breast cancer detection with quantitative transcriptomics

Year: 2025

Type: article

Abstract: Accurate identification of HER2-low breast cancers remains challenging using standard IHC. We analyzed 3182 breast tumors using transcriptomics, revealing detectable ERBB2 mRNA in 86% of IHC 0 cases. Pathological complete response was most prevalent in anti-HER2-treated patients with highest ERBB2 expression. Our results demonstrate that transcriptomics can sensitively detect HER2 expression and stratify patients beyond IHC classification, supporting its use as a complementary biomarker for guiding anti-HER2 therapy decisions.

Source: npj Breast Cancer

DOI: 10.1038/s41523-025-00817-9

Authors: Maria-Anna Misiakou, Maj-Britt Jensen, Maj-Lis Talman, Bent Ejlertsen, Maria Rossing

Institutions: Copenhagen University Hospital, Rigshospitalet, Danish Breast Cancer Cooperative Group, University of Copenhagen

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,790